glp 1 for chronic kidney disease GLP-1 receptor agonists and next-generation metabolic hormone therapies in GLP‑1 medications are becoming more

Chu, R., Li, R., Wang, C

Employers are balancing coverage (many see it as a competitive benefit) with tighter utilization: mandatory prior auth, step edits requiring patients to fail cheaper modalities first, periodic re-authorization, and increasingly, coupling coverage with lifestyle management programs

Zhygalina-Hritsenyuk M

Future of transdermal GLP-1 delivery Research on true pharmaceutical-grade transdermal GLP-1 delivery is underway: Microneedle array patches : Use tiny dissolvable needles to deliver medication just below the skin Enhanced transdermal systems : Employ special technologies to improve skin penetration Controlled-release formulations : Designed for sustained delivery over days or weeks Animal studies have shown promising results, with some experimental patches achieving blood levels comparable to those of injections